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A B S T R A C T
Numerous films with a dissolved or dispersed active principle within a polymeric matrix have been described in
literature. However, the incorporation of solid crystals into the films may influence several relevant properties.
Additionally, it has been reported that different polymeric matrices lead to films presenting a different perfor-
mance. The aim of this work was to evaluate the effect of the combination of chitosan with carrageenan (κ-, λ-,
and ι-) as matrices, and of the miconazole nitrate incorporation method, on the films behavior. Mechanical
properties, drug release and antifungal activity were evaluated. The state of the drug in the films was analyzed
by different techniques. Films showed a homogeneous surface and a thermal protective effect on the drug. The
combination of chitosan and λ-carrageenan leads to films with the highest values of tensile and mucoadhesive
strength. Films with solubilized drug displayed slightly higher elongation at break, tensile and mucoadhesive
strength and faster drug release than those with suspended miconazole nitrate. However, no differences were
found regarding the antifungal activity of the different formulations including time-to-kill curves.
1. Introduction
Candidiasis is probably the most prevalent opportunistic fungal in-
fection of the oral cavity. Its incidence varies depending on age and
certain predisposing factors, being immunocompromised patients the
most affected ones (Spampinato and Leonardi, 2013; Van Roey et al.,
2004). Several antifungal drugs used for the treatment of the buccal
infections are administered orally and topically. Topical agents, applied
directly to the infected area, proved to be quite effective to treat su-
perficial candidiasis while systemic chemotherapeutic drugs are re-
commended in the management of invasive fungal infections that
cannot be treated locally (Spampinato and Leonardi, 2013). In recent
years, a remarkable interest has been focussed on the topical route for
the treatment of fungal pathologies due to the specific physiological
characteristics of the oral cavity (Morales and McConville, 2011; Van
Roey et al., 2004). The treatment of oral candidiasis usually requires
long-term administration of antifungal agents. The success of the
treatment against this oral pathology depends, among other factors, on
the pharmaceutical dosage form used for its administration in the oral
cavity. An ideal dosage form should be able to maintain the drug
concentration higher than the minimal inhibitory concentration in the
salivary fluid, over an extended period, reducing the dosage frequency.
Among the different formulations, which may be applied in mouth are
buccal films. Buccal films offer advantages over adhesive tablets in
terms of flexibility and comfort (Morales and McConville, 2011).
Moreover, buccal films are also suitable for protecting wound surfaces,
which is important when the infection produces ulcerative lesions
(Llabot et al., 2007). An ideal buccal film should be flexible, elastic, and
soft but adequately resistant in order to prevent breakage due to stress
from oral activities (Tejada et al., 2017). Moreover, it must also possess
good bioadhesive strength so that it can be retained in the mouth for
long periods (Tejada et al., 2017). In addition, polymeric films provide
distinct advantages over other oral formulations including acceptability
and compliance among geriatric and pediatric patients (Sievens-
Figueroa et al., 2012), and also, exhibit manufacturing advantages in-
cluding continuous manufacturing capabilities (Dixit and Puthli, 2009;
Sievens-Figueroa et al., 2012). The characteristics of buccal polymeric
films are highly dependent on the type and concentration of the
https://doi.org/10.1016/j.ijpharm.2018.07.023
Received 17 April 2018; Received in revised form 14 June 2018; Accepted 5 July 2018
⁎ Corresponding author at: Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, 24 (2000) Rosario, Argentina.
E-mail address: leonardi@iquir-conicet.gov.ar (D. Leonardi).
International Journal of Pharmaceutics 548 (2018) 431–442
Available online 06 July 2018
0378-5173/ © 2018 Elsevier B.V. All rights reserved.
T
polymers used. Furthermore, several polymers such as chitosan (CH),
kappa-carragenan (k-C), lambda-carragenan (λ-C) and iota-carragenan
(ι-C) (Hambleton et al., 2009; Kalsoom Khan et al., 2017; Karbowiak
et al., 2006; Kaur and Kaur, 2012; Khajuria et al., 2018; Kianfar et al.,
2012; Lima et al., 2013; Shahbazi et al., 2016) were used to develop
drug delivery systems,. CH (Fig. 1A), a polysaccharide obtained from
the deacetylation of chitin, is a well known cationic biodegradable and
biocompatible natural polymer which show film forming capacity and
mucoadhesive properties due to the interaction between its positively
charged amino groups and negatively charged sialic acid residues in
mucus (Tang et al., 2014). Additionally, CH cations exhibit good affi-
nity to form polyelectrolyte complexes with anionic biopolymers.
Carrageenans are water-soluble galactose polymers extracted from
red seaweed, which are extensively used in the food and pharmaceu-
tical industries as gelling and stabilizing agents (Cha et al., 2002). The
isomers of carrageenan (κ-, ι-, and λ-carrageenan) differ in the number
and position of the ester sulfate groups on the galactose units: kappa has
one, iota has two, and lambda has three (Kalsoom Khan et al., 2017)
(Fig. 1B–D). It has also been reported that the gelling power of κ-and ι-
carrageenans impart excellent film-forming properties (Park et al.,
2001). Even though the interest in pharmaceutical films has increased
according to publications in recent years (Chonkar et al., 2016; Krampe
et al., 2016; Montenegro-Nicolini and Morales, 2017; Morales and
Brayden, 2017; Park et al., 2001; Real et al., 2013; Trastullo et al.,
2016; Woertz and Kleinebudde, 2015), more research is needed in order
to overcome potential limitations and increase general patient accep-
tance (Sievens-Figueroa et al., 2012). Regarding the films, numerous
systems have been described in literature where the active ingredient
have been dissolved or dispersed within the polymeric material (El-
Kamel et al., 2007; Gallagher and Corrigan, 2000; Kolakovic et al.,
2012; Perugini et al., 2003). While water-soluble drugs exist in the
dissolved state or as a solid solution, water-insoluble drugs should be
homogenously distributed in a film formulation in order to have ac-
ceptable drug content uniformity (Sievens-Figueroa et al., 2012). Mi-
conazole nitrate (MN) is an azole antifungal agent currently available to
treat mucosal or systemic infections caused by Candida spp
(Spampinato and Leonardi, 2013). The Biopharmaceutics classification
system classified MN as Class II (drugs having dissolution-limited
bioavailability because of their poor water solubility). This poor water
solubility may hinder the formulation of buccal films with dissolved
MN. However, the incorporation of solid MN crystals into the films,
even in very small sizes, may influence properties like mechanical
strength, adhesiveness, homogeneity, drug release, and rate of anti-
fungal activity. To our knowledge, there is no previous research
studying the influence of drug incorporation on the final characteristics
of polymeric films and, in addition, formulation of buccal films con-
taining CH in combination with κ-, λ-, and ι-carrageenan to deliver MN,
has not been previously investigated. Thus, the aim of this work was to
evaluate whether the combination of those biopolymers and the man-
ufacturing techniques applied to formulate MN buccal films would
modify its physicochemical properties. Mechanical properties, drug
release, and antifungal activity, were then evaluated. Additionally, the
drug solid state in the films was thoroughly analyzed by X-ray dif-
fraction, thermogravimetric analysis, differential thermogravimetric
analysis, and differential scanning calorimetry.
2. Materials and methods
2.1. Materials
CH (230 KDa average molecular weight and 80.6% of N-deacetyla-
tion) was supplied by Aldrich Chemical Co. (Milwaukee, WI, USA),
Food-grade κ, ι, and λ-carrageenan samples were kindly donated by
FMC BioPolymer (Philadelphia, PA), and MN pharmaceutical grade was
purchased from Parafarm, (Buenos Aires, Argentina). All other chemi-
cals were of analytical grade.
2.2. Film preparation
Polymeric films were prepared by the solvent casting method. The
formulated films are described in Table 1. Briefly, CH solution (3% w/
v) was prepared dispersing CH in a solution of 10% v/v lactic acid
(pH=2.67), polysorbate 80 (tween 80) 0.1% v/v was added to this
solution in order to obtain a homogeneous dispersion of the final sus-
pension (when polymers and drugs are mixed). In parallel, aqueous acid
solutions (0.15% v/v lactic acid) of κ, ι, or λ-carrageenan (1% w/v),
were prepared, stirred overnight, and filtered through Miracloth®
(Calbiochem-Novabiochem Corp., San Diego, CA). Each polymeric
Fig. 1. Chemical structures of different polymers employed in the development of polymeric films. A: CH, B: κ-C, C: ι-C and D: λ-C.
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solution was then dripped over CH solution under magnetic stirring
(Boecco stirrer, Germany) at 80 °C to avoid precipitation. After that,
PEG 400, employed as a plasticizer (30% w/w), was then added and
stirred at 200 rpm for 2 h. Finally, MN (8% w/w) was added by sieving
(840 μm) to the mixture and stirred for 2min (Table 1, formulations
8–14). The suspensions were cast on 9 cm diameter Petri dishes and
dried (48 h at 40 °C, and 58% relative humidity (RH)). Dried films were
removed from the Petri dishes and conditioned in a chamber (72 h at
25 °C and 58% RH). A similar procedure was performed but this time
MN was solubilized in PEG 400 employed as a plasticizer (stirring at
200 rmp for 2 h), and added to the polymeric solutions (Table 1, for-
mulations 15–21). The films used in the different tests were selected
based on the lack of physical defects such as holes, cracks, or bubbles.
2.2.1. Film characterization
2.2.1.1. Folding endurance, film thickness, and mechanical properties
2.2.1.1.1. Folding and thickness. Folding endurance was determined
by repeatedly folding the films at the same place until they broke or
were folded 300 times (Avachat et al., 2013). The thickness of each film
was obtained with a digital micrometer (Schwyz, China). Ten
measurements were made around and in the center of each film
(Libio et al., 2016).
2.2.1.1.2. Mechanical properties. A texturometer (Mecmesin
Multitest 2.5d, Mecmesin, Sterling, VA, U.S.A.) with a 10 N load cell
was used to analyze the mechanical strength of the films, which had
previously been conditioned (24 h at 25 °C and 58% RH) and cut into
strips (7 mm wide and 60mm long) to evaluate tensile properties
(Tejada et al., 2017). Each sample was clamped between tensile grips,
the distance between the grips was 30mm and the crosshead speed was
0.05mm/s. The parameters obtained from stress/strain curves were
tensile strength (TS), and elongation at break (E). TS is a measure of the
maximal force per original cross-sectional area that the film could
support before breaking, whereas E was determined as the percentage
of change in the length of each sample with respect to the initial
distance between grips, and it estimates the capacity of the film to
extend before breaking. For each film, three replicate measurements
were performed.
2.2.1.2. In vitro mucoadhesive strength. A texturometer (Mecmesin
Multitest 2.5d, Mecmesin, Sterling, VA, U.S.A.) was employed to
analyze the mucoadhesive strength of each film. The force required to
detach each formulation from a disc of porcine gum (obtained from
“Paladini” slaughterhouse, V.G. Galvez, Argentina) was measured. A
portion of each film (2.5 cm diameter) was added to the upper end of
the cylindrical probe and gum discs (obtained by punch biopsy and
hydrated with 0.5 mL artificial saliva for 2min) were horizontally
attached to the lower end of the cylindrical probe by using double-sided
adhesive tape. Artificial saliva consisted of phosphate buffer saline
solution (2.38 g Na2HPO4, 0.19 g KH2PO4 and 8.00 g NaCl per liter of
distilled water adjusted with phosphoric acid to pH 6.75) (Borges et al.,
2015; Peh and Wong, 1999). Each film remained in contact with the
gum for 1min and it was then moved upwards at a constant speed
(1.0 mm/min). The test was carried out in triplicate. The force required
to detach each film from the gum disc was determined from the
resulting force/time plot. (Eouani et al., 2001).
2.2.1.3. Swelling index. An accurately weighed portion of the films
(2.5 cm diameter) was immersed in 0.5 mL of artificial saliva at 37 °C
(Giovino et al., 2013). At predetermined time intervals, the films were
carefully removed, and the excess adhering moisture was gently blotted
off and weighed. After that, 0.5 mL of artificial saliva was added again.
The swelling index (SI) was calculated using the weights of dried (W0)
and swollen (Wt) films (Equation (1). The test was carried out in
triplicate (Libio et al., 2016).
= −SI W W Wt 0 0 (1)
2.2.1.4. Scanning electron microscopy. The morphology of raw materials
and films was analyzed using a scanning electron microscopy (SEM,
AMR 1000, Leitz, Wetzlar, Germany). A conductive and double-sided
adhesive was employed to mount the film samples on an aluminum
sample support. Samples were coated with a fine gold layer (15min at
70–80mTorr) in order to make them conductive before obtaining
micrographs. Examinations were carried out using an accelerating
voltage of 20 kV and magnifications of 200×, 500× and 1000×.
2.2.1.5. X-Ray diffraction. An automated X’Pert Phillips MPD
difractometer (Eindhoven, The Netherlands) was employed to the
experiments. Data collection was carried out in transmission mode. X-
ray diffraction patterns were recorded using CuKa radiation
(λ=1.540562 Å), 40 kV (voltage), 20mA (current) and 0.02° (steps)
in the interval 2Θ=10°–50°. Parallel beam geometry, by means of an
X-ray lens and a graphite monocromator placed before the detector
window, was employed to assure low peak broadening and background.
Data acquisition and evaluation were performed with the Stoe Visual-
Xpow package, Version 2.75 (Germany).
2.2.1.6. Thermal analysis. Thermal gravimetric analysis (TGA) was
performed with a TG HI-Res thermal analyzer (TA Instruments) at a
heating rate of 10 °C/min from room temperature to 650 °C in air flow.
Differential Scanning Calorimetry (DSC) tests were performed in a
Linseis DSC PT1000, from 25 to 250 °C at a heating rate of 10 °C/min
under nitrogen.
2.2.1.7. Dissolution studies. Dissolution studies were performed in
900mL of distilled water containing 1% v/v PEG 400 at 37 °C, using
a USP XXIV apparatus II (Hanson Research, SR8 8-Flask Bath, Ontario,
Canada) with paddles rotating at 50 rpm. MN 80mg was dispersed in
the dissolution medium while different films (containing 80mg MN)
were fixed to the central shaft using cyanoacrylate adhesive. Three
samples of 5mL each were taken using a 0.45 μm filter, at different
times: 0, 10, 20, 30, 40, 50, 60, 90, 120, 180, 240, 300 and 360min.
The amount of MN released was determined by UV spectrometry using
the drug absorption band (272 nm). Dissolution studies were also
performed with unloaded films and each absorbance obtained at
different times was used as blank. An equal volume of the dissolution
medium was added after each sample extraction to maintain a constant
volume.
Table 1
Films composition.
Number Formulation CH (%
w/w)
ι-C (%
w/w)
κ-C (%
w/w)
λ-C (%
w/w)
MN added
1 CH 100 0 – – –
2 ι-C 0 100 – – –
3 CH-ι-C 75 25 – – –
4 κ-C 0 – 100 – –
5 CH-κ-C 75 – 25 – –
6 λ-C 0 – 100 – –
7 CH-λ-C 75 – 25 – –
8 CH-MN-SUS 100 0 – – Suspended
9 CH-ι-C-MN-SUS 75 25 – – Suspended
10 ι-C-MN-SUS 0 100 – – Suspended
11 κ-C-MN-SUS 0 – 100 – Suspended
13 CH-κ-C-MN-SUS 75 – 25 – Suspended
12 λ-C-MN-SUS 0 – 100 – Suspended
14 CH-λ-C-MN-SUS 75 – 25 – Suspended
15 CH-MN-SOL 100 0 – – Solubilized
16 CH-ι-C-MN-SOL 75 25 – – Solubilized
17 ι-C-MN-SOL 0 100 – – Solubilized
18 κ-C-MN-SOL 0 – 100 – Solubilized
19 CH-κ-C-MN-SOL 75 – 25 – Solubilized
20 λ-C-MN-SOL 0 – 100 – Solubilized
21 CH-λ-C-MN-SOL 75 – 25 – Solubilized
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2.2.1.8. Halo zone test. The test was carried out on Agar plates
(150mm diameter) containing Mueller-Hinton agar, supplemented
with 2% glucose (2 g/100mL) and 0.5 µm/mL methylene blue (MB),
at a depth of 4.0 mm following the guidelines of the disk diffusion
method described in CLSI document M44-A2 (Clinical and Laboratory
Standards Institute, 2008). Candida albicans ATCC 10231, provided by
American Type Culture Collection (ATCC), Rockville, MD, USA. Prior to
each experiment, the isolate was aerobically cultured at 35 °C for 24 h.
Cell suspension inocula were obtained according to the reported
procedures and adjusted in sterile distilled water to 0.5 McFarland
standard (approximately 1–5·106 CFU/mL) (Postigo et al., 2017). The
agar surface was inoculated by dipping sterile cotton swabs into a cell
suspension and by streaking the plate surface in three directions. The
plate was allowed to dry for 20min, and the films were then placed
onto the surface of agar, and incubated in air at 28 °C for 24 h. The halo
zone of complete inhibition was determined using a caliper and the
mean value for each organism was recorded (Wang et al., 2015).
2.2.1.9. Time-to-kill analysis. The time-to-kill curves were performed to
assess the exposure time required to kill a standardized C. albicans
inoculum. The test organisms (10mL, approximately 104 CFU/ml) were
incubated with agitation in Sabouraud dextrose broth medium
containing different films (2.5 mm) or an equivalent MN content.
Aliquots of control and samples were taken and diluted at 0, 15, 30,
45, 60, 90, 120, 150min, and 24 h, and the microorganisms were
counted by spreading each sample onto a Sabouraud dextrose agar
plate. The plates were incubated for 24 h and the viable colonies were
evaluated. The kill curves were constructed by plotting the CFU/ml
surviving at each time point in the presence and absence of the films or
MN raw material (Tonglairoum et al., 2015a,b).
2.2.1.10. Statistical analysis. Analysis of variance was used, and when
the effect of the factors was significant, the Tukey multiple ranks
honestly significant difference test was applied (GraphPad Prism 5).
Differences at p < 0.05 were considered significant.
3. Results and discussion
3.1. Films’ thickness folding endurance and mechanical properties
Films based only on ι-C, κ-C and λ-C were unable to be analyzed.
Films based only on κ-C were brittle while films based on ι-C and λ-C
were soft, elastic and presented high adhesive behavior to the Petri
dishes, and therefore these formulations were disposable.
Thicknesses of different formulations (loaded and unloaded) are
shown in Fig. 2A. As can be observed, all formulations ranged from
0.55 ± 0.08 to 0.93 ± 0.05mm. These thickness values are adequate
to avoid discomfort when applied, because an ideal buccal film should
exhibit a thickness between 50 and 1000 μm (Nair et al., 2013). No
significant differences (p > 0.05) between the thickness of the dif-
ferent formulations were observed. Therefore, based on these results,
the incorporation of the drug into the film, whether as a solid or as a
solution, does not affect the thicknesses of the formulation. Regarding
the folding endurance, all formulations loaded and unloaded with MN
were folded at least 300 times without breaking, meeting the assay
criteria (Avachat et al., 2013). This study was carried out to evaluate
film flexibility, which is highly desirable in order to avoid easy dis-
location from the site of application or film breaking during adminis-
tration, and also to ensure that the film can be easily handled to pro-
duce comfort and a secured application (Avachat et al., 2013).
When tensile strength was analyzed (Fig. 2B) significant differences
were found between loaded and non loaded CH-carrageenans films
(p < 0.001). The tensile strength values of CH unloaded films were
significantly improved when CH was combined with carragenans
(p < 0.05). In particular, tensile strength of CH-λ-C films was the
highest one, which could be due to the fact that λ-C presents three ester
sulfate groups per galactose units, while κ-C presents only one (Fig. 1).
Thus, more anionic groups are available to interact with CH by ionic,
electrostatic and/or hydrogen bonding, which may bring about the
improvement in the tensile strength. On the other hand, no differences
were found between films loaded with suspended or solubilized MN.
However, a tendency can be observed, showing a lower tensile strength
for the films loaded with suspended drug (Fig. 2B).
Formulations based only on CH were those that presented higher
elongation at break values. The elongation at break of different for-
mulations showed a similar tendency (Fig. 2C). Elasticity values were
the highest for unloaded films followed by films loaded with solubilized
MN and finally by those loaded with suspended drug.
The elongation of CH unloaded films decreased significantly when
CH was in combination with the anionic polymers (p < 0.001), giving
more rigid matrices. The elongation between the composited films was
highest for the combination CH-κ-C and decreased with the improve-
ment of the negative charges per galactose units in the carragenan.
Thus, the more available charges, the more interactions and the less
elasticity.
Desired mechanical properties of buccal films will vary depending
on the formulation goals and the applied procedure (Morales and
Fig. 2. Characterization of different films. A: Thickness, B: Tensile strength, C:
Elongation at break. Each bar represents the mean value (n= 10 for thickness,
n=3 for tensile strength, n=3 for elongation at break) and errors bars refer to
standard deviation (SD). ***p < 0.001, *p < 0.05, ns: p > 0.05.
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McConville, 2011). An ideal buccal film should be flexible, elastic, soft
but adequately strong to withstand breakage due to the stress of mouth
activities (Szabó et al., 2013). Therefore, films displaying relatively
high tensile strength and elongation at break are preferred for such
application (Morales et al., 2013). In this work, as it was mentioned
above, the elongation at break was reduced when CH was combined
with carrageenans and even more when the number of anionic charges
in carrageenans was increased (Fig. 1C) but this effect could probably
be resolved increasing the plasticizer concentration in the films.
Suyatma et al, analyzed the effect of the addition of 0, 5, 20 and 40%
w/w of PEG 400 as plasticizers to CH films and found that the use of
PEG 40% w/w produced the highest flexibility of CH films (Suyatma
et al., 2005). On the other hand, it has also been reported that platicizer
concentrations above a critical value can exceed the compatibility limit
with biopolymers and produce a phase separation. Consequently, the
plasticizer is excluded (Vieira et al., 2011) giving the idea that the
plasticizer concentration could be increased but only up to certain
limits to be compatible with the polymers.
The films based only on CH showed a smooth and homogeneous
surface (Fig. 3A). A similar behavior was observed in films based on
combinations CH-κ-C (Fig. 3E) and CH-λ-C (Fig. 3G). On the other
hand, CH-ι-C films presented a shrink, irregular and non-uniform sur-
face (Fig. 3F). This is probably due to the strong interactions between
positive charges of CH and negative charges of the helical structures in
ι-C. Both κ-C and ι-C form a network of three-dimensional double he-
lices, resulting from the crosslinking of the adjacent spiral chains that
contain sulphate groups which are oriented towards their external part,
and thus available to interact with CH (Campo et al., 2009). Probably,
the numbers of sulphate groups (two per disaccharide) exposed, in the
case of ι-C, produce stronger interactions with CH than in the case of κ-
C (one per disaccharide). On the other hand, in λ-C, the sulphate groups
are oriented towards the internal part, which could avoid the strong
interactions with CH (Campo et al., 2009). Although the thickness,
tensile strength, and elongation of films based on CH-ι-C are in
Fig. 3. Morphological surface of different films. A: CH, B: κ-C, C: ι-C, D: λ-C, A1: CH-MN-SUS, B1: κ-C-MN-SUS, C1: ι-C-MN-SUS, D1: λ-C-MN-SUS, A2: CH-MN-SOL,
B2: κ-C-MN-SOL, C2: ι-C-MN-SOL, D2: λ-C-MN-SOL, E: CH-κ-C, F: CH-ι-C, G: CH-λ-C, E1: CH-κ-C-MN-SUS, F1: CH-ι-C-MN-SUS, G1: CH-λ-C-MN-SUS, E2: CH-κ-C-MN-
SOL, F2: CH-ι-C-MN-SOL, G2: CH-λ-C-MN-SOL.
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adequate range, their irregular and non-uniform surface shows some
degree of non-homogeneous interactions between the polymers. This
could generate irreproducible results, therefore, films based only on CH
and combinations of CH-κ-C and CH-λ-C were selected for further
analysis.
3.2. In vitro mucoadhesive strength
Film mucoadhesive strength values are shown in Fig. 4. The ob-
tained mucoadhesive value for unloaded CH was 0.35 N similar to
previously published values (Patel et al., 2007). As it was observed,
unloaded combinations between oppositely charged films improved the
mucoadhesion of CH (p < 0.05). This could be due to the fact that
more groups are present in the films to interact with the mucin, more
often in the case of λ-C than in the case of κ-C. Thus, the formation of
strong hydrogen bonds and ionic interactions between the polymer
functional groups and the mucosa has a clear effect on the strength of
mucoadhesion layer. Additionally, it has been reported that water in-
teracts with polymer chains and softens the polymer matrix, allowing
for entanglement of domains of mucin molecules and polymer chains
(Morales et al., 2014). In the case of CH-λ-C, the matrices were more
rigid (Fig. 2B); however, its high charge density might be the de-
termining step in its mucoadhesive behavior. There are probably, more
interactions with CH, but also more free charges in these films to in-
teract with the mucin. When MN was loaded, the mucoadhesive
strength of films was decreased significantly. Similar results were re-
ported by Naffe et al when MN was loaded in buccal patches based on
different polymers such as sodium carboxymethyl cellulose, chitosan,
polyvinyl alcohol, hydroxyethyl cellulose and hydroxypropylmethyl
cellulose (Nafee et al., 2003). No differences were found between films
loaded with solubilized and suspended MN; however, a tendency can be
observed: films loaded with suspended MN showed slower adhesive-
ness. When MN was loaded (solubilized or suspended), no differences
were found between the adhesiveness of the films. When MN is solu-
bilized into the matrix, the charges of the polymers may interact with
the drug, reducing the free available charges to attach to the gingival
zone. On the other hand, when MN was suspended into the matrix, the
crystals on the film surface probably reduce the superficial area with
mucoadhesive capacity. As it can be observed in Fig. 4 mucoadhesive
force values of loaded films ranged from 0.11 N to 0.25 N showing that
these films posses moderated mucoadhesive properties (Morales and
McConville, 2011). It is important to say that the mucoadhesive
strength of the developed polymeric films could be improved by adding
some polymers presenting high mucoadhesive properties such as Guar
gum, Carbopol®, Polycarbophil, Poly(ethylene oxide) or Sodium car-
boxymethyl cellulose (Morales and McConville, 2011) to the matrix in
order to fulfill the requirements for an ideal buccal film.
3.3. Swelling index
Films swelled in different ways depending on the polymers used in
the formulations and the presence of suspended or solubilized MN
(Fig. 5). Films based only on CH disintegrated after 30min (Fig. 5A). On
the other hand, films based on polymers with opposite charge densities
produced a low mass equilibrium and an important increase in the
disintegration time. All formulations based on polymer combinations
swelled for at least 24 h without undergoing disintegration. After 24 h,
the swelling index values were 0.71, 0.77 and 0.73 for CH-λ-C, CH-λ-C-
MN-SUS and CH-λ-C-MN-SOL, respectively, while for films CH-κ-C, CH-
κ-C-MN-SUS and CH-κ-C-MN-SOL, the obtained values were 0.61, 0.64,
Fig. 4. Film mucoadhesive strength values. Each bar represents the mean value
(n=3) and errors bars refer to SD. ***p < 0.001, **p < 0.01, *p < 0.05, ns:
p > 0.05.
Fig. 5. Film swelling and disintegration in 0.5 mL of artificial saliva (n=3 ± SD).
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and 0.58. It may be postulated that ionic interactions between the
molecules induced stronger non-covalent binding, leading to films
which are less swellable and which present a better structure to be
administered for buccal treatments. Among the different films, it can be
observed that formulations containing λ-C showed higher swelling
values than those containing κ-C. This could be explained by the higher
number of charges present in λ-C, and the fact that the structural
conformation of the films could be different. As mentioned before, κ-C
forms a network of three-dimensional double helices which results from
the crosslinking of the adjacent spiral chains that contain sulphate
groups oriented towards their external part, and thus more available to
interact with CH than sulphate groups present in λ-C (which are or-
iented towards the internal part, thus avoiding strong interactions). If
so, although the interactions with CH produced more rigid matrices (as
observed in Fig. 2), in the case of λ-C more charges are free to interact
with artificial saliva, showing higher swelling degree. This result is
consistent with that obtained in the mucoadhesion assay. Films loaded
with suspended MN showed the highest swelling degree (even more
than unloaded films). This is probably due to the fact that the presence
of a particulate material disrupts the continuum of the polymeric ma-
trix, allowing for more free space and increasing the matrix surface
exposed to the solvent (Morales et al., 2014). In contrast, when films
are loaded with solubilized MN, some of the charges of the matrixes
could interact with the drug, reducing the number of free charges
available to interact with the solvent, resulting in the lowest swelling
values.
As mentioned before, films based only on CH showed the highest
swelling degree and they were disintegrated between 30 and 40min
after starting the assay. CH can be categorized as superabsorbent and
CH free groups play an important role in water uptake because of their
hydrophilic nature (Karki et al., 2016). These kinds of matrices are not
adequate for the aim of this work and, therefore, combinations of CH-κ-
C and CH-λ-C were selected for further analysis.
Fig. 6. Scanning electronmicroscopy micrographs of MN, polymers and superficial sections of films. A–D: raw materials, A: MN, B: λ-C, C: CH, D: κ-C, E and H: film
superficial sections, E and G: CH-λ-C, F and H: CH-κ-C, I: MN crystal in CH-λ-C-MN-SUS, J: MN crystal in CH-κ-C-MN-SUS.
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3.4. Scanning electron microscopy
The morphology of MN, CH, κ-C, λ-C and superficial surface of films
based on polymer combinations are shown in Fig. 6. As observed, MN
appears as irregular small crystals (10–20 μm, Fig. 6A) while CH
(Fig. 6C) are blocks (100–300 μm) presenting a smooth surface with few
smaller particles (20–40 μm). Finally, κ-C (Fig. 6B) and λ-C (Fig. 6D)
appear as irregular and fibrous blocks (50–200 μm) with non-uniform
surface. All films based on CH-κ-C and CH-λ-C were homogeneous, but
showed a highly different surface. While the surface of films based on
CH-λ-C were slightly rough (Fig. 6F and 6H), those based on CH-κ-C
proved to be rough with a porous surface and presented a three-di-
mensional interconnected microstructure (Fig. 6E and 6G). The inter-
connection between pores could be assigned to the crosslinking net-
work formation, probably due to the special conformation of κ-C,
exposing its sulphate groups oriented towards their external part, which
could allow for strong but non-homogeneous interaction with CH. Films
based on CH-λ-C showed a dense and compact structure, suggesting
high structural integrity and adequate compatibility between the
components (Villacrés et al., 2014).
When films were loaded with suspended MN, small crystals of the
drug were identified in the film surface (Fig. 6I and J); while in the case
of films loaded with solubilized MN, no crystals were observed.
3.5. X-ray diffraction
The X-ray study was carried out to characterize the state of MN in
the films. The X-ray patterns of the MN raw material, polymers and
films are shown in Fig. 7.
The MN spectra showed a typical crystalline pattern with sharp and
narrow peaks at diffraction angles (2θ): 13.05°, 14.49°, 15.59°, 16.22°,
18.55°, 20.80°, 21.57°, 22.95°, 25.19°, 26.15°, 27.32°, 29.9°, 31.82°,
33.12°, 36.6°, and 40.69°. A peak at around 20° related to the anhydrous
CH crystals was observed in CH raw material (Li et al., 2009). Likewise,
κ-C presented two crystalline peaks at 21° and 29°. Finally λ-C showed
an amorphous structure (Fig. 7A). Films did not show any clear peaks
corresponding to crystalline MN (Fig. 7B and C); only a small peak was
observed at 16.22° which corresponds to the drug in CH-λ-C-MN-SUS
(Fig. 7B). The absence of peaks in the spectra of films could suggest that
MN is in an amorphous state even in films where the drug was sus-
pended, or that MN reduced partially its crystallinity during the film
formulation, or that the MN concentration in the films is below the
detection limit (Leuner and Dressman, 2000). Based on visual analysis
(Fig. 3) and SEM studies, where several crystals were observed on CH-
λ-C-MN-SUS and CH-κ-C-MN-SUS (Fig. 6I and J), the absence of peaks
in the case of films loaded with suspended MN may be because either
cristallinity has been partially reduced or the concentration of the drug
in the film is below the detection limit.
On the other hand, in the case of films loaded with solubilized MN
the drug could be in an amorphous state. In the X-ray spectra of films
Fig. 7. X-ray diffraction patterns of MN raw material, polymers and films.
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based on oppositely charged polymers, the typical peak of CH dis-
appeared, suggesting that the introduction of anionic polymers into CH
disrupted its crystalline structure. It has been reported that amino and
hydroxyl groups in CH form complexes with anionic polymers, which
may break the hydrogen bonding between amino groups and hydroxyl
groups in CH, resulting in an amorphous structure (Li et al., 2009).
Similarly, in the case of κ-C, its three-dimensional double helices re-
sulting from the crosslinking of the adjacent spiral chains that contain
sulphate groups externally-oriented could be disrupted by the presence
of CH, losing its crystalline structure.
3.6. Thermal analysis
Fig. 8 shows the TGA and DTGA curves of MN, polymers and se-
lected films. From the curves, it is possible to observe that the CH
polymer presents degradation in a single stage whose maximum de-
gradation speed is centered at 297 °C, which corresponds to the depo-
lymerization thereof (de Britto and Campana-Filho, 2004). A small peak
can also be observed between 40 and 100 °C that is related to the water
absorbed and corresponds to the first mass drop in the TGA curve (de
Britto and Campana-Filho, 2004). Both κ-C and λ-C exhibited similar
degradation steps: the first one, centered at around 60 °C may corre-
spond to the loss of adsorbed and bound water, the second and main
one is centered at around 230 °C, and two more at higher temperatures
Fig. 8. TGA (A and C) and DTGA (B and D) curves. A and B: MN, polymers and CH-λ-C films, C and D: MN, polymers and CH-κ-C films.
Fig. 9. DSC curves for MN and films based on CH-λ-C and CH-κ-C.
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(320–400 °C) (Rane et al., 2014; Sadeghi, 2012). On the other hand, the
drug, MN, has a broad peak centered at 305 °C. In the case of the films
without MN, four different steps can be recognized: 1) 60 °C (water), 2)
185 °C (associated with plasticizer), 3) 230 °C (associated with carra-
geenan) and 4) 320 °C (near to CH decomposition). The peaks at tem-
peratures higher than 400 °C could be associated with the decomposi-
tion of the original degradation products. When MN was incorporated
to the films, the difference was related with the degradation tempera-
ture of the drug.
Fig. 9 shows the DSC curves for MN and films based on CH-λ-C and
CH-κ-C. In the case of MN, whereas the first peak is associated with the
melting of the drug, the second one can be related with the starting of
the degradation. It is important to note that, in all cases, polymers act as
a thermal protective on MN, increasing the temperature of the last peak
whereas no evidence of the melting point of the drug inside the films
was present, in accordance with X-ray results. Again, in the case of films
loaded with suspended MN the absence of the melting point of the drug
is probably because MN partially reduced its crystallinity or because
MN concentration in the films is below the detection limit, while in the
case of films loaded with solubilized MN, the drug could be in amor-
phous state.
3.7. Dissolution studies
Films loaded with solubilized MN showed the fastest dissolution
rate (Fig. 10). After 60min assay, these films allowed the release of
100% of the drug, while those films loaded with suspended MN released
70% of drug, and only 20% of MN was released from MN raw material.
No significant differences were found between matrices based on κ-C
and λ-C (p > 0.05).
The improvement in the dissolution rate of MN when it was sus-
pended in the films is probably because polymeric matrices enhanced
the wettability of the drug and also reduced drug agglomeration, in-
creasing surface area and improving MN dissolution rate (Craig, 2002).
On the other hand, films loaded with solubilized MN could improve the
drug dissolution due to the fact that MN is in an amorphous state. As
reported, the amorphous state of a drug leads to high-energy drug solid
state resulting in enhanced solubility and dissolution rate (Jermain
et al., 2018).
3.8. Halo zone test
A paper disk containing MN powder, and unloaded CH, CH-κ-C and
CH-λ-C films were designed as controls. MN raw material produced
inhibition zones around 18mm while unloaded films based only on CH
showed hales around 6mm, which is in agreement with the reported
antifungal activity of the polymer (Elsabee and Abdou, 2013). Also,
unloaded CH-κ-C and CH-λ-C films produced smaller growth inhibition
zones around 1.5 mm which are probably due to the presence of CH in
the formulations (Fig. 11). As regards the loaded films, no significant
differences (p > 0.05) were found between films loaded with solubi-
lized or suspended MN as all formulations showed similar halos
Fig. 10. Dissolution studies of MN raw material and films, performed in 900mL of distilled water containing 1% PEG 400 at 37 °C (n=3 ± SD).
Fig. 11. Growth inhibition halos around the disc and comparison between the
antifungal activities of MN raw material, CH, and assayed films. Each bar re-
presents the mean value (n=6) and errors bars refer to SD. ***p < 0.001, ns:
p > 0.05.
Fig. 12. Time-to-kill curves of CH and selected films (n=3 ± SD).
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between 40 and 50mm. However, a tendency can be observed in
Fig. 11: all films loaded with solubilized MN presented, in average,
higher inhibition zones than films loaded with suspended MN. On the
other hand, significant differences (p < 0.001) were found between
loaded formulations and MN powder. Thus, it can be postulated that
films were able to inhibit C. albicans growth by the combination of two
factors: the MN released from the formulations and the antimicrobial
properties of CH. Probably, MN raw material, a hydrophobic drug, was
unable to dissolve in the culture medium and therefore its dissolution/
diffusion performance was incomplete, producing smaller inhibition-
halos than films.
As observed in Fig. 10, the dissolution of films loaded with solubi-
lized MN was faster than those loaded with the suspended one.
Therefore, it was expected that more dissolution/diffusion in C. albicans
cultures medium will produce higher halos of inhibition. However, as
mentioned, the inhibition halos produced by films loaded with sus-
pended or solubilized MN did not show significant differences. This fact
is probably related to the employed methodology that requires the
placement of films onto the surface of agar followed by air-incubation
at 28 °C for 24 h before the halo zone is read. It could be postulated that
during incubation both, suspended and solubilized MN, are able to
spread reaching the same inhibition hale.
3.9. Time-to-kill analysis
Fig. 12 shows the time-to-kill profiles of CH and the selected films
loaded with MN. It was observed that the control curve showed an
increase in the number of colony forming units compared with the in-
itial inoculum. On the other hand, after 150min CH polymer produced
a reduction of the C. albicans culture (from 10,000 CFU/mL to
2500 CFU/mL). It has been reported that low concentrations of CH
produces a series of alterations of ion homeostasis and metabolism of
the yeast while at high concentrations it may act as permeation agent
for bacteria and fungi (Peña et al., 2013). Thus, when CH is used at
concentrations higher than 1.0mg/mL not only a fungistatic but also a
fungicidal activity is observed. In this assay the CH concentration
(when placing unloaded films into the medium) was 0.6mg/mL,
therefore, the polymer presented fungistatic activity. All formulations
containing the drug allowed a complete eradication of the C. albicans
culture after 15min assay. Almost super imposable profiles were ob-
tained for CH-κ-C and CH-λ-C with suspended or solubilized MN. The
minimum inhibitory concentration (MIC) and the minimum fungicidal
concentration (MFC) using MN for oropharyngeal C. albicans strains
were found to be 3.9 μg/mL and 13.7 μg/mL respectively (D’auria et al.,
2005). It was observed that both kinds of films (loaded with suspended
or solubilized MN) allowed to reach the fungicidal MN concentration at
15min assay and, as consequence, no colony forming units were ob-
served after this time. This result shows that the antinfungal activity of
these formulations is not modified when the drug is loaded either
suspended or solubilized into de matrix.
4. Conclusions
In this work, mucoadhesive buccal films based on CH and carra-
geenans were successfully developed and characterized. Films based on
CH-κ-C and CH-λ-C combinations, showed a thermal protective effect
on the drug, presented homogeneous surface, high tensile strength,
moderated elongation at break and adhesiveness, and were able to
swell during 24 h without suffering disintegration. It was observed that
the combination of CH and λ-C led to films with the highest tensile and
mucoadhesive strength values, and presented the highest swelling.
These facts are probably because some of the sulfate groups of λ-C
interact with CH while others are free in the matrices; the latter groups
could interact with mucin and artificial saliva. Regarding the in-
corporation of suspended or solubilized MN into the polymeric films at
the concentration selected did not produce significant changes in the
mechanical behavior of the prepared polymer-based films. It can be
concluded from obtained results that no significant differences were
detected in the mechanical behavior between suspended and solubi-
lized MN in polymer-based films. However, a tendency was observed:
films with solubilized MN displayed slightly higher tensile strength,
elongation at break and mucoadhesive strength than those with sus-
pended MN. On the other hand, swelling was slightly improved when
the drug was suspended, probably because particulate material, ob-
served by SEM, disrupts the continuity of the polymeric matrix, al-
lowing more free space increasing the surface of the matrix exposed to
the solvent. DRX and thermal analysis were unable to detect the MN,
probably due to the fact that in films loaded with suspended MN, the
drug partially reduced its crystallinity below the detection limit, while
in the case of films loaded with solubilized MN, the drug could be in an
amorphous state. Drug release was faster when MN was solubilized in
the matrix, probably because the amorphous state of the drug leads to a
high-energy solid state, resulting in enhanced dissolution rate.
However, no differences were found regarding the antifungal activity of
the different formulations even when analyzing time-to-kill curves.
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